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fractionation. The purpose of this study was to define the 
maximum tolerated dose of an hypofractionated RT 
treatment based on IGRT-IMRT-SIB technique with final boost 
by IGRT-stereo-VMAT technique. 
Materials and Methods: Intermediate-high risk CAP patients 
(NCCN categories) were enrolled in consecutive cohorts 
treated with increasing RT doses. In the first cohort patients 
received a dose of 45 Gy (1,8 Gy/fraction) on pelvic lymph 
nodes and a concurrent boost with total dose of 65 Gy (2,6 
Gy/fraction) on prostate +/- seminal vesicles, using IMRT-SIB 
technique after implantation of intraprostatic fiducials. In 
the second cohort patients also received a final boost of 5 Gy 
in single fraction with stereotactic-VMAT technique. An 
adjuvant hormone therapy of 6 (intermediate risk) and 24 
months (high risk) was prescribed. Proctoscopy was 
performed to evaluate rectal toxicity using the Wachter-
Score one year after the end of RT. The study design allowed 
dose escalation in case of < 3/25 (12%) evaluable patients 
with Wachter-score > 3. 
Results: Sixty patients were recruited in the first cohort and 
139 patients in the second cohort (total: 199 patients; 
median age: 73 years (range: 50-82); median PSA: 8,7 ng/ml 
(range: 0,15-83,0); cT3-4: 41,8%; Gleason score > 7: 29,6%). 
The 3-year biochemical recurrence-free survival was 91,6%. 
The analysis results are reported in the table. 
Conclusions: In a dose-escalation study, the use of IGRT-
VMAT-SIB technique with hypofractionated total dose of 65 
Gy resulted feasible in terms of acute and late toxicity, with 
positive preliminar results in terms of biochemical control. 
Stereotactic boost (with total dose of 70 Gy) did not increase 
toxicity rates.  
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Purpose/Objective: Some evidence suggests that there is a 
significant correlation between acute and late rectal toxicity 
after radiotherapy. The purpose of this analysis is to test this 
hypothesis in a large sample of patients (597), treated with 
adjuvant radiotherapy (RT) +/- hormonal therapy (HT). 
Materials and Methods: The results, in terms of acute and 
late toxicity, were analyzed and compared in a population of 
patients enrolled in 8 different clinical studies. Acute toxicity 
was evaluated according to the RTOG scale and late toxicity 
was evaluated according to the RTOG-EORTC scale. The 
cumulative actuarial late toxicity was calculated using the 
Kaplan-Meier method and comparison of survival curves was 
performed by logrank test (univariate analysis) and Cox's 
proportional hazard method (multivariate analysis, using as a 
covariate: radiotherapy dose, fractionation, prophylactic 
lymph node irradiation, adjuvant hormonal therapy ). 
Results: 597 patients, treated with radiotherapy were 
evaluated; 91.5% of patients received adjuvant hormonal 
therapy (LH-RH analogue: 49,9%; antiandrogen agent 
[bicalutamide, 150 mg per day]: 41.6%). The results of 
statistical analysis are shown in the table. There is a 
statistical correlation between acute and grade 1 and 2 late 
rectal toxicity, both at univariate and multivariate analysis. 
 
 
Conclusions: The results of this analysis confirm the close 
correlation between acute and late radio-induced rectal 
toxicity. These results suggest that excessive early damage to 
the 'acute-respoding' component of the rectal wall plays an 
important role in the genesis of late toxicity. Radiation 
proctitis is thus confirmed, at least in part, as a 
'consequential' effect. This justifies the use of acute toxicity 
as surrogate end-point of late complications in dose-finding 
studies on radiation therapy of prostate cancer.  
   
PO-0726   
Is seminal vesicle invasion detected on MRI still the same 
poor prognostic factor as it used to be?  
F. Pos1, U.A. Van der Heide1, W.D. Heemsbergen1 
1Netherlands Cancer Institute Antoni van Leeuwenhoek 
Hospital, Radiotherapy Department, Amsterdam, The 
Netherlands  
 
Purpose/Objective: Traditionally, seminal vesicle invasion 
(T3b) was diagnosed by digital rectal examination or 
transrectal ultrasound. In the recent years diagnostic MRI has 
become available, a technique that is much more sensitive 
and can detect even minimal invasion. It is, however, unclear 
whether a MRI based T3b (MR-T3b) has the same poor 
prognosis as a clinically staged T3b (cT3b). We therefore 
compared the clinical outcome of MR T3b with that of cT3b 
prostate carcinoma (PC). 
Materials and Methods: Patients (n=90, cohort A) were 
treated with (78 Gy) image-guided IMRT for localized PC 
between 2008 – 2010 and had diagnostic signs of SV invasion 
on the planning MRI; 60 % was prescribed 3y of adjuvant 
hormonal treatment (AHT) because of clinical high-risk 
features. Pre-RT screening for positive LN was performed. 
Patient and tumor characteristics were compared with a 
previous cohort B (n=87) treated in 1997 – 2002 (68 Gy or 78 
Gy) with 3D conformal RT (32 % received 3y AHT). Freedom 
from failure (FFF) was scored according the Phoenix 
definition. Multivariate Cox regression (MV) was applied to 
determine significant predictive factors for freedom from 
failure (FFF). 
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Results: Patient characteristics are shown in Table 1 and FFF 
in Figure 1. FFF at 4y was 77 % in cohort A versus 55 % in 
cohort B (Fig 1-L, p=0.02). Adjuvant hormonal treatment 
(AHT) prescription was mainly based on pre-MR findings in 
Cohort A, and introduced for high-risk patients during the 
recruitment period of cohort B. As a result, more patients in 
Cohort A received AHT (p<0.01). Although in both cohorts the 
maximum age was around 80 years, Cohort A contained more 
older patients (p<0.01) and also more aggressive tumors 
(p<0.01). Low/intermediate risk patients with 0-6m AHT, had 
worse FFF < 5.5y (p=0.04) compared to high-risk with 3 AHT 
in cohort A (Fig 1-R). The corresponding 
FF
  
 
 
Conclusions: There was no significant cohort effect at MV 
analysis, suggesting that the observed difference in FFF is 
mainly caused by AHT prescription, implying that MR-T3b 
tumors show similar aggressive disease as clinically 
determined T3b tumors. In line with this, the results also 
suggest that long-term AHT might also be beneficial for MR-
T3b patients with otherwise low-intermediate risk features.  
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Purpose/Objective: Hyperthermia (HT) is a (neo)adjuvant 
treatment modality that increases the effectiveness of 
radiotherapy or chemotherapy by heating the tumour area to 
41–43 °C. Recently a multi-centre phase III randomized 
clinical trial comparing adjuvant treatment of non-muscle 
invasive bladder cancer (NMIBC) using Mytomycin C (MMC) 
with and without loco-regional HT has started. 
A good clinical effect requires a well-controlled thermal 
dose, as treatment outcome is temperature dependent. This 
necessitates reliable thermometry and detailed 
thermophysical fluid models to accurately monitor and 
predict the temperature distribution inside the bladder and 
bladder wall. Recently, we presented the 'umbrella' probe, a 
novel multi-sensor temperature probe that accurately 
measures the temperature of both the bladder wall and the 
fluid inside. However, detailed thermophysical fluid models 
are still lacking in the present, in-house developed HT 
Treatment Planning System (HTPS). 
This study's final goal is to optimize the temperature 
distribution and registration during HT bladder treatment 
using 3D steering of the power deposition. To this end we are 
developing a high resolution HTPS capable of modelling 
convective heat transport inside the bladder. 
Materials and Methods: We created a convective thermal 
model and set up a phantom experiment to test its accuracy. 
A porcine bladder filled with 60 ml 0.9 % NaCl solution was 
placed in tissue equivalent gel. The phantom was heated 
with the AMC-4 deep HT device for 900 s at 400 W to reach a 
clinical temperature rise. This was repeated with 120 ml 
saline solution to cover the clinically relevant volume range. 
Inside the bladder, temperatures were measured using the 
umbrella probe, on the outside we used copper-constantan 
thermocouple probes. We simulated this experiment using 
both the current HTPS and the new convective model using 
the OpenFOAM toolkit. Both were compared to the 
measurements. 
Results: The temperature distribution computed by the 
convective model was in much closer agreement with the 
measurements in and around the bladder than that by 
current HTPS. The temperature measurements in the 60 ml 
case are practically identical to that in the 120 ml case. 
Comparison of the temperature distribution between the new 
convective model and the current HTPS showed good 
agreement within the solid regions of the phantom; however, 
both models differed significantly inside the fluid and in the 
immediately surrounding tissue, i.c. the bladder wall (Figure 
1). This range of temperature differences exceeded 1 °C in 
either direction, demonstrating the need for the new model. 
The current HTPS generally underestimated the bladder wall 
temperature and overestimated the temperature at the 
bladder centre. 
